Skip to main content

OZEMPIC (Novo Nordisk Pharmaceuticals Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
177 working days (255)
Active ingredients
semaglutide (rys)
Registration type

OZEMPIC (solution for injection) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

  • as monotherapy when metformin is not tolerated or contraindicated.
  • in addition to other medicinal products for the treatment of type 2 diabetes.

Help us improve the Therapeutic Goods Administration site